In cancer-associated thrombosis, DOACs reduce VTE...

In cancer-associated thrombosis, DOACs reduce VTE and increase clinically relevant nonmajor bleeding vs. LMWH at 3 to 12 mo.

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Oncology: [Formula: see text] Hematology: [Formula: see text].

Godoy A; Douketis JD

Annals of Internal Medicine, Vol. 178, No. 11,

American College of Physicians

November 1, 2025

10.7326/annals-25-04088-jc

1056-8751

James Demetrios Douketis